WEST LAFAYETTE, Ind. – A biotech company founded by a Purdue University chemistry professor has completed a $10.25 million Series A round of funding to further study its new influenza treatment that has shown rapid results.
West Lafayette-based Eradivir plans to conduct a Phase 2a challenge study of its EV25 influenza treatment, the university said Monday. EV25 was built on a drug platform technology created by Eradivir co-founder and Purdue chemistry professor Philip Low, who is on the faculty of the Purdue Institute for Drug Discovery and the Purdue Institute for Cancer Research.
Eradivir CEO Martin Low, brother of Philip and a co-founder of the company, said EV25 in preclinical models has outperformed existing standards of treatment.
Full story: Purdue startup secures $10M in Series A funding for flu treatment research – Inside INdiana Business
